

The chemistries and consequences of DNA and RNA methylation and demethylation

Franziska R. Traube and Thomas Carell

Department of Chemistry, Ludwig-Maximilians-Universität München, Butenandtstrasse, Munich, Germany

ABSTRACT

Chemical modification of nucleobases plays an important role for the control of gene expression on different levels. That includes the modulation of translation by modified tRNA-bases or silencing and reactivation of genes by methylation and demethylation of cytosine in promoter regions. Especially dynamic methylation of adenine and cytosine is essential for cells to adapt to their environment or for the development of complex organisms from a single cell. Errors in the cytosine methylation pattern are associated with most types of cancer and bacteria use methylated nucleobases to resist antibiotics. This Point of View wants to shed light on the known and potential chemistry of DNA and RNA methylation and demethylation. Understanding the chemistry of these processes on a molecular level is the first step towards a deeper knowledge about their regulation and function and will help us to find ways how nucleobase methylation can be manipulated to treat diseases.

ARTICLE HISTORY

Received 10 January 2017
Revised 4 April 2017
Accepted 6 April 2017

KEYWORDS

Cytosine modifications; DNA modifications; Epigenetics; methyltransferases; RNA modifications; TET enzymes

Since the discovery of (deoxy)adenosine (dA, A), (deoxy)cytidine (dC, C), (deoxy)guanosine (dG, G), (deoxy)thymidine (dT, T) and uracil (U) in the early 20th century as the information carrying building blocks, which form the basis for RNA and DNA, various modifications of these nucleosides were discovered (Fig. 1).^{1,2} Particularly in transfer-RNA (tRNA) but also in rRNA (rRNA), modified bases are central elements, needed to fine tune the translation of the genetic code.^{3–6} In rRNA of bacterial pathogens, many methylated bases are present to block binding of small molecules that work as translation inhibitors, resulting in a resistance against antibiotics such as aminoglycosides.⁷ More recently it was discovered that also mRNA (mRNA) contains modified bases. Although it is not yet fully understood what the function of these bases are, it was revealed that the modification chemistry is to some extent reversible. This suggests that the modification and de-modification chemistry has a novel and yet unexplored regulatory function. In this regard N6-methylated adenine (m6A) is the best analyzed modification, but most recently also the reversible formation of N6, C2'-dimethyl adenine (m6Am) was discovered. According to current knowledge, reversible chemistry on modified RNA bases is limited to methyl groups, which are introduced by methyltransferases and removed by demethylases. DNA, in contrast, as the prime carrier of genetic information in the biosphere, is structurally less complex and only few modified bases are known. Most prominent is the methylated base 5-methyl deoxycytosine (5mdC). Ideas about the potential chemistry of methylations and demethylation are the focus of this review. For other aspects, the following excellent reviews can be consulted.^{1,2}

5mdC is the most abundant modified base in genomic DNA of eukaryotes and also present in the DNA of prokaryotes.^{8–10}

In mammals, 5mdC typically reaches global levels between 1 and 5% in genomic DNA.^{11,12} Methylated adenine (6mA), which is the DNA equivalent to m6A in RNA, is another DNA modification that is under intensive investigation at the moment. Whereas 6mA is a well-characterized modification in bacterial DNA, its presence was only recently shown in several higher eukaryotic organisms.^{13,14} In *Caenorhabditis elegans*, where 5mdC is not detectable, 6mA is dynamically regulated and linked to other epigenetic marks¹⁵ and in early embryos of *Drosophila melanogaster*, 6mA levels are high, but decrease fast during development, resulting in very low 6mA levels in adult tissue.¹⁶ In the unicellular green alga *Chlamydomonas reinhardtii*, 6mA was discovered in 84% of the genes, where it is mainly located at transcription start sites.¹⁷ Recently, it was reported that mammalian DNA, including human and mouse, also contains 6mA.^{13,18} There, 6mA seems to be distributed across the genome, but absent in gene exons,¹⁹ and 6mA-demethylation in mouse embryonic stem cell (mESC) DNA was shown to correlate with ALKBH1 depletion.¹⁸ These findings question the previous paradigm that DNA modifications in mammalian genome are limited to cytosine residues. However, when our group tried to confirm these results by a novel ultrasensitive UHPLC-MS method, we were not able to detect 6mA in mESC DNA or DNA from mouse tissue, whereas *Chlamydomonas* DNA, which served as a positive control, delivered the expected positive result.²⁰ These observations suggest that 6mA might be present at defined time points in mammalian DNA, but is not an epigenetic mark. In the coming years, the question whether 6mA is a relevant modification in mammalian DNA or not will thus certainly be under intensive investigation.




Figure 1. Examples of methylated and oxidized bases found in RNA and DNA.

Chemistry of RNA and DNA base methylation

The addition of the methyl-group to DNA and RNA bases (Fig. 2) is catalyzed by DNA- and RNA-methyltransferases that use *S*-adenosyl-methionine (SAM) as an active methyl-group donor.^{21–23} While the methyltransferases that methylate RNA bases are now under extensive investigations, the enzymes that catalyze the methylation of dC in DNA are well characterized. In mammalian cells, 3 active DNA-methyltransferases (DNMTs: DNMT1, DNMT3a and DNMT3b) exist.^{24,25} DNMT3a and 3b are *de novo* DNMTs, which methylate canonical dC bases.²⁶ In contrast, DNMT1 maintains the methylation status during cell division, where the template strand is already methylated, but the newly synthesized strand is lacking methylation.²⁷ As such, DNMT1 converts the methylation of dC into an inheritable modification that can be transferred during reproduction.^{28,29}

DNMTs and thus cytosine methylation is essential in those multicellular organisms, where it exists. The presence or absence

of 5mdC is associated with various important cellular functions, such as transcription control, X-chromosome silencing and genomic imprinting.²⁸ A global deletion of only one of the 3 DNMTs leads to severe cellular aberrations and is therefore lethal in early embryogenesis (DNMT1 and 3b) or postnatal (DNMT3a).^{26,30} During differentiation the “methylome” is highly dynamic and a celltype-characteristic 5mdC pattern is established during this process.³¹ While 5mdC is located to a CpG-dinucleotide context in the majority of somatic cells, non-CpG methylation is also present in embryonic stem cells, many pluripotent progenitor cells and adult brain. However, CpG-methylation is also dominating here.^{32–34} Cytosine-methylation in vertebrates occurs in all types of DNA sequence contexts, including repetitive and regulatory sequences, genes and transposable elements; in contrast to invertebrates, where mostly repetitive sequences are methylated.³⁵ The majority of cytosines in a CpG-context, depending on the cell type up to 80%, are methylated, leaving so-called CpG islands (CGI) of actively transcribed genes as unmethylated patterns in a CpG-context.^{36,37}




Figure 2. Mechanism of methylation leading to the formation of *het-CH₃* and *C-CH₃* connectivities in RNA and DNA.

CGIs are regions of high CpG frequency over a length of at least 500 base pairs compared with the bulk genomic DNA and found in 40% of promoter regions in the mammalian genome, with even higher levels (60%) in the human genome.^{38,39} Symmetric methylation of CpG:GpC islands is consequently a hallmark of silenced genes.^{40,41}

The enzymatic mechanism of how methyltransferases methylate DNA and RNA bases is shown in Fig. 2. Centers with a certain nucleophilicity like the amino group of the RNA base A can attack the SAM coenzyme directly leading to immediate methylation. This type of direct methylation is certainly operating for the formation of m₂A, 4mC or m₆Am. SAM as nature's "methyl iodide" is hence reactive enough to methylate even weak nucleophilic centers such as the exocyclic amino groups of A, which feature, as an sp²-hybridized N-atom only a very weak nucleophilic lone pair at the N-atom. This type of direct methylation creates bases, which possess the methyl group attached to a heteroatom establishing a *het-CH₃* system. This will be important in the context of active demethylation (*vide infra*).

In contrast to the formation of *het-CH₃* connections, methylation of the dC base in DNA at position C5 is far more complex. The C5-center features no nucleophilicity at all, making direct methylation impossible. Nature solves this problem by exploiting a helper nucleophile (R-SH, Fig. 2). The DNMT enzymes attack the dC base first with a nucleophilic thiol in a 1,6 addition reaction. This establishes a nucleophilic enamine substructure (green in Fig. 2), which can subsequently be methylated with the SAM cofactor. Importantly, the helper nucleophile is subsequently eliminated, thereby re-establishing the aromatic system. This more complex enzymatic transformation allows nature to methylate non-nucleophilic carbon atoms to create *C-CH₃* connectivities which feature a strong and stable C-C single bond.

Chemistry of demethylation

To establish the reversibility needed for switching biochemical processes, nature requires to remove the attached methyl groups.

Removal of *het-CH₃* groups found predominantly in RNA was found to occur with the help of α -ketoglutarate (α -KG) dependent oxidases. These proteins contain a reactive Fe(II) center, which reacts to a strongly oxidizing Fe(IV) = O species with oxygen under concomitant decarboxylation of α -KG to succinate (Fig. 3).⁴² The Fe(IV) = O species is able to abstract a H-atom from the *het-CH₃* group to form a *het-stabilized het-CH₂•* radical, which reacts with the Fe-bound hydroxyl radical to form a *het-CH₂-OH* hemiaminal/acetal functionality.

However, these structures are unstable. In water, they decompose in a spontaneous reaction under loss of formaldehyde to give the unmethylated compound. It is interesting that formaldehyde is formed as a byproduct of this reaction because it is typically a rather toxic compound. It needs to be seen how this molecule is detoxified in the context of the demethylation reaction. Particularly well studied is the removal of the N₆-methyl group from m₆A to revert into the canonical RNA base A. So far 2 α -KG dependent oxidases were found to catalyze the oxidation. One is the fat mass and obesity-associated protein (FTO) protein and the second is ALKBH5. It was shown, that knockdown of FTO led to increased amounts of m₆A and in turn overexpression of FTO resulted in decreased m₆A levels.⁴³ Alkbh5-deficient mice had a similar effect as FTO knockdown in human cells and resulted in increased m₆A levels of the mRNA.⁴⁴ The demethylation activity of both proteins is comparable, although ALKBH5 shows direct demethylation, whereas FTO-mediated demethylation is supposed to create hm₆A and f₆A as intermediates.^{42,44}

In 2009 it was found that also 5mdC is further enzymatically oxidized in a stepwise fashion to give first 5-hydroxymethyldeoxycytosine (5hmdC), followed by 5-formyldeoxycytosine (5fdC) and 5-carboxydeoxycytosine (5cadC). "Ten-11 translocation" (TET) enzymes, which are Fe²⁺/ α -KG dependent dioxygenases, were discovered to catalyze this iterative 5mdC oxidation reaction.^{45,46} Regarding the first oxidation step that transforms 5mdC to 5hmdC, the Fe²⁺/ α -KG catalyzed reaction generates a stable *C-CH₂-OH* connectivity, which is as a primary alcohol stable in water (Fig. 3). 5hmdC is consequently a




Figure 3. Oxidation of m₆A followed by decomposition of the hemiaminal to A and oxidation of 5mdC to stable 5hmdC.




Figure 4. Potential mechanism of chemically induced active demethylation with a potential immediate re-methylation.

stable DNA base modification and it was suggested that the base has indeed epigenetic functions. For example, 5hmC constitutes 0.6% of all nucleotides in Purkinje neurons, a special neural cell type of the cerebellum, and 0.032% of all nucleotides in embryonic stem (ES) cells.^{45,47} The highest 5hmC levels in fully differentiated tissues were found in the brain with up to 1% of all cytosines.^{48,49} Evidence accumulates that 5hmC in a given gene is able to accelerate transcription and it is not surprising that 5hmC is mainly present in the promoter of actively transcribed genes.^{50,51}

TET enzymes are in this sense required to orchestrate the transcriptional activity of genes. In vertebrates, TET proteins exist in 3 different types (TET1 – TET3) that do not differ regarding their chemistry, but seem to have different spatio-temporal activity. Whereas TET1 is mostly expressed in stem cells, TET3 is upregulated during differentiation and the most abundant TET enzyme in fully differentiated cells.^{52–54} A global TET3-knockout is lethal in embryogenesis, because it prevents epigenetic reprogramming during differentiation.⁵⁵ It is interesting, that the presence of 5hmC in mammalian DNA was described first already in 1972.⁵⁶ It took more than 30 y to confirm that 5hmC is really present in substantial amounts that are highly depending on the cell and tissue type.⁵⁷

The further oxidized bases 5fdC and especially 5cadC (Fig. 4) could not be associated yet with distinct cellular functions, but for 5fdC it was reported that it might have regulatory purposes and is also a stable epigenetic mark.⁵⁸ In accordance with these previous findings, a recently reported single-cell 5fdC-sequencing method called CLEVER-seq revealed that the generation of 5fdC in promoter regions precedes the upregulation of gene expression.⁵⁹ Despite this faint evidence for

epigenetic functions, 5fdC and 5cadC are currently mainly considered to be intermediates on the way of an active DNA demethylation process. DNA demethylation is a crucial process of cell development. Especially during fertilization (paternal part of the genome), early embryogenesis (maternal part of the genome) and the development of germ cells, DNA demethylation takes place in a genome-wide manner, allowing a broad reprogramming of the fertilized oocyte and the cells in the early embryo.^{60–63} But not only during development, also in fully differentiated cells, it occurs at specific sites of the genome. In brain, for example, locus-specific DNA demethylation and *de novo* methylation is induced by neural activation, arguing that DNA demethylation is important for normal brain function, including memory formation and learning.^{64–66} DNA demethylation can take place either actively, which means replication-independent, or passively when DNMT1 does not methylate the nascent DNA strand in hemi-methylated DNA after replication. Passive demethylation occurs, when DNMT1 is absent or blocked during the replication process, which happens for example during early embryogenesis to ensure the demethylation of the maternal genome.⁶⁷ Interestingly, 6mA demethylation in *Drosophila* is catalyzed by *Drosophila*'s TET homolog (DMAD or dTet). DMAD depletion results in higher 6mA levels, but unchanged 5mC patterns, and is lethal at pupa stage or shortly after.¹⁶ DMAD and TET possess similar catalytic active Cys-rich and DSBH domains, however, 6mA-demethylation activity was not observed yet for mammalian TET enzymes.¹⁶

Although oxidation of 5hmC to 5fdC and 5cadC creates stable molecules due to the lack of a β -atom in β -position, it is discussed that both could be turned into unstable structures




Figure 5. Active demethylation via base excision repair. Two possibilities are discussed: A direct removal of 5fdC and 5cadC in xC:dG base pairs or removal of a deaminated 5hmdU in a 5hmdU:dG mismatch by BER glycosylase.

upon further chemical manipulation. A chemically attractive mechanism requires that 5fdC and 5cadC are attacked by a helper nucleophile, preferentially a thiol group at the C6 position, in a Michael-type reaction (Fig. 4). Hydratization of 5fdC and tautomerization of the reacted 5fdC and 5cadC allows us to formulate a “ β -imino-type” substructure that is prone to deformylation and decarboxylation (red arrows in Fig. 4). Indeed, we could show that reaction of 5fdC and 5cadC with a thiol-nucleophile leads to spontaneous deformylation and decarboxylation showing that the suggested chemistry is feasible. There is currently no evidence that this type of chemistry occurs *in vivo* but we could show that stem cell lysates feature a decarboxylating activity.⁶⁸ Interesting is the observation that deformylation and decarboxylation of 5fdC and 5cadC after reaction with a thiol nucleophile leads to a reaction intermediate (boxed in Fig. 2 and 4) that is the key intermediate observed already during methylation of dC to 5mC by the DNMTs. It is therefore tempting to speculate that DNMT enzymes are involved in the deformylation and decarboxylation maybe followed by immediate re-methylation. Although this reaction sequence would follow chemical logic, it needs to be clarified in the near future, if such reactions occur indeed in nature. It was, however, shown that C5-DNA-methyltransferases are indeed able to remove formaldehyde from 5hmdC, converting 5hmdC directly to dC, therefore supporting these ideas.⁶⁹

In this context, it is interesting to note that 5hmC and 5fC were also discovered in RNA. In human cells at tRNA position C34, the oxidation of the corresponding RNA base 5mC to 5fC is catalyzed by the $\text{Fe}^{2+}/\alpha\text{-KG}$ dependent enzyme ALKBH1, which is also responsible for m1A demethylation in mammalian tRNA.^{70,71} Interestingly, 5hmrC was not detected as an intermediate in the ALKBH1-dependent 5mC oxidation.⁷⁰ In *Drosophila*, 5hmrC was discovered in polyadenylated RNA and is associated with enhanced mRNA-translation efficiency back to normal level, when 5mC has lowered the

efficiency.⁷² Surprisingly, the oxidation reaction is catalyzed by *Drosophila*'s TET homolog dTet that is also responsible for 6mA demethylation, but does not oxidize 5mC.^{16,72} Moreover, there is evidence that TET enzymes are also responsible for 5mC oxidation,^{73,74} but at the moment it is not clear whether TET-mediated 5hmrC or 5fC formation are stable or rather transient modifications.

In contrast to the chemical mechanism of active demethylation discussed above, strong evidence exists that active demethylation via formation of 5fdC and 5cadC is also linked to base excision repair (BER), which repairs also mismatches caused by deamination of 5hmdC to 5hmdU (Fig. 5). This mechanism includes excision of 5fdC or 5cadC and subsequent activation of BER. The dG/dT mismatch specific thymine DNA glycosylase (TDG) recognizes dG/dT mismatches, but with an even higher activity it excises 5fdC or 5cadC, but not 5mC and 5hmdC, *in vitro*.⁷⁵ This reactivity was not observed for other DNA glycosylases. Evidence that TDG excises 5fdC and 5cadC also *in vivo* is given by the fact that 5fdC and 5cadC levels are 5–10 times increased in TDG-deficient ES cells compared with the wildtype.⁷⁶ However, TET/TDG-mediated demethylation is very unlikely to be the only demethylation mechanism. It rather occurs at defined promoter regions in the genome than in a genome-wide manner. First, TDG-activity causes abasic sites.⁷⁷ If this happened genome-wide, it may impair genomic stability, which is crucial for correct development. Second, TDG knockout starts to be lethal not before embryonic day 12.5 and TDG levels are very low in the zygote, where the paternal genome is demethylated.^{78,79}

Most recently it was suggested that nature may not need to oxidize 5mC to 5fdC and 5cadC for demethylation and that a third TET-independent pathway has to exist. In the zygote, the most drastic demethylation occurs when 5mC is globally erased from the paternal part of the genome, while the maternal part is shielded from demethylation. DNA-demethylation of

the paternal pro-nuclei is replication- and TET-independent, since 5hmdC levels increase after 5mdC levels have dropped and global demethylation can be detected in Tet3-deficient zygotes.⁸⁰ It might be that deamination of genomic 5mdC to dT and subsequent dT/dG mismatch repair are the mechanism behind this observation.⁸¹ However, this would also impair genomic stability.

Implication of misguided methylation and demethylation

Whereas the distribution of 5mdC and 5hmdC is tightly regulated to ensure the anticipated functionality of a cell and its response to DNA damage, one hallmark of cancer cells is their completely different methylation and hydroxyl-methylation pattern.^{82,83} In many cancer types, the global methylation levels are decreased, while promoter regions of important regulatory and tumor suppressor genes are hypermethylated and therefore silenced.⁸⁴ One example is the hypermethylation of the promoter region of HIC1, which is a transcriptional repressor of SIRT1, a survival protein (proto-oncogene) that is consequently upregulated.⁸⁵ It was also shown that certain CGIs are coordinately methylated in some tumor cells, which is called “CpG island methylator phenotype.”^{86–88} Since TET1 was initially discovered in 2002 as a fusion protein to MLL1 H3K4 methyltransferase in patients with acute lymphoblastic leukemia, which is characterized by mutations in the MLL1 protein, it was considered to be an oncogene.⁸⁹ Only when the biologic function of the TET enzymes was elucidated in 2009, it was proven a few years later that TET enzymes are actually tumor suppressors that are silenced in various types of tumors. Decreased levels and activity of TET1 and therefore reduced 5hmdC levels are associated with haematopoietic malignancies, colon, breast, prostate, liver and lung cancers, which show greater levels of proliferation and for breast cancer increased invasion rates as a direct consequence of TET1 downregulation.^{90–93} TET2 mutations and consequently decreased 5hmdC levels occur in various myeloid malignancies, including chronic myelomonocytic leukemia, myeloid proliferative neoplasm and acute myeloid leukemia.^{82,94,95} Mutations in the genes of isocitrate dehydrogenase (IDH) 1 and 2 lead to the production of D-2-hydroxyglutarate (D-2HG), a metabolite that inhibits TET2 activity for example in AML and MPN, but also in malignant gliomas, resulting in a dramatic decrease of 5hmdC levels.⁹⁶ Interestingly, IDH1/2 and TET2 mutations seem to be mutually exclusive in these types of tumor, with IDH1/2 mutations being the ones with higher oncogenic potential.^{97,98} Recent results show that not only mutations in TET genes or their inhibition by cancer metabolites are important for tumorigenesis, but also tumor hypoxia is responsible for reduced TET activity.⁹⁹

There is more and more evidence that epigenetics and metabolism are closely connected not only via D-2HG in cancer metabolism, but also in normal cells.^{100,101} As an intermediate in the tricarboxylic acid (TCA) cycle and part of nitrogen catabolism through deamination of glutamate, α -KG is one of the key metabolites. Since it is the co-substrate of TET enzymes and other dioxygenases involved in epigenetic regulation, such as histone lysine demethylase, it links epigenetics directly to metabolism. Levels of α -KG are

rate limiting for TET activity and higher α -KG levels result in higher TET activity with direct impact on differentiation processes.¹⁰² Depending on the cell type and status, α -KG can either promote self-renewal or induce differentiation.¹⁰³ In brown adipose tissue (BAT) development, for example, TET3 mediates cell commitment to BAT by demethylating the Prdm16 promoter. AMP activated protein kinase α 1 (AMPK α 1) influences α -KG levels positively and therefore increase TET3 activity.¹⁰⁴ Glutamate and glutamine metabolism increases α -KG levels, leading to self-renewal in pluripotent mouse embryonic stem cells, while succinate supply leads to differentiation.¹⁰² Additionally, succinate and also fumarate, another 2 intermediates of TCA cycle, show an inhibitory effect on TET enzymes *in vitro*.¹⁰⁵

In the future, it will be challenging not only to prove the existence, but to reveal the distinct biologic functions of the various DNA and RNA modifications that exist. The role of the modified bases in mRNA are currently under extensive investigation and for DNA, especially the functions of 5hmdC in regulatory and learning processes in brain, but also during development and in cancer cells are of great interest.

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

Acknowledgments

FRT thanks the Boehringer Ingelheim Fonds for a PhD fellowship. We thank the Deutsche Forschungsgemeinschaft for financial support through the programs: SFBs 646, 749 and 1032, as well as the SPP1784. Further support is acknowledged from the Excellence Cluster CiPS^M (Center for Integrated Protein Science).

References

- Breiling A, Lyko F. Epigenetic regulatory functions of DNA modifications: 5-methylcytosine and beyond. *Epigenetics Chromatin* 2015; 8:24; PMID:26195987; <https://doi.org/10.1186/s13072-015-0016-6>
- Chen K, Zhao BS, He C. Nucleic acid modifications in regulation of gene expression. *Cell Chem Biol* 2016; 23:74–85; PMID:26933737; <https://doi.org/10.1016/j.chembiol.2015.11.007>
- Duechler M, Leszczynska G, Sochacka E, Nawrot B. Nucleoside modifications in the regulation of gene expression: Focus on tRNA. *Cell Mol Life Sci* 2016; 73:3075–95; PMID:27094388; <https://doi.org/10.1007/s00018-016-2217-y>
- Penzo M, Galbiati A, Trere D, Montanaro L. The importance of being (slightly) modified: The role of rRNA editing on gene expression control and its connections with cancer. *Biochim Biophys Acta* 2016; 1866:330–8; PMID:27815156; <https://doi.org/10.1016/j.bbcan.2016.10.007>
- Sloan KE, Warda AS, Sharma S, Entian KD, Lafontaine DL, Bohnsack MT. Tuning the ribosome: The influence of rRNA modification on eukaryotic ribosome biogenesis and function. *RNA Biol* 2016; 16:1–16; PMID:27911188; <https://doi.org/10.1080/15476286.2016.1259781>
- El Yacoubi B, Bailly M, de Crecy-Lagard V. Biosynthesis and function of posttranscriptional modifications of transfer RNAs. *Annu Rev Genet* 2012; 46:69–95; PMID:22905870; <https://doi.org/10.1146/annurev-genet-110711-155641>
- Lioy VS, Goussard S, Guerineau V, Yoon E-J, Courvalin P, Galimand M, Grillot-Courvalin C. Aminoglycoside resistance 16S rRNA methyltransferases block endogenous methylation, affect translation efficiency and fitness of the host. *RNA* 2014; 20:382–91; PMID:24398977; <https://doi.org/10.1261/rna.042572.113>

8. Ehrlich M, Wang RY-H. 5-Methylcytosine in eukaryotic DNA. *Science* 1981; 212:1350-7; PMID:6262918; <https://doi.org/10.1126/science.6262918>
9. Kahramanoglu C, Prieto AI, Khedkar S, Haase B, Gupta A, Benes V, Fraser GM, Luscombe NM, Seshasayee AS. Genomics of DNA cytosine methylation in *Escherichia coli* reveals its role in stationary phase transcription. *Nat Commun* 2012; 3:886; PMID:22673913; <https://doi.org/10.1038/ncomms1878>
10. Ehrlich M, Gama-Sosa MA, Carreira LH, Ljungdahl LG, Kuo KC, Gehrke CW. DNA methylation in thermophilic bacteria: N⁴-methylcytosine, 5-methylcytosine, and N⁶-methyladenine. *Nucleic Acids Res* 1985; 13:1399-412; PMID:4000939; <https://doi.org/10.1093/nar/13.4.1399>
11. Ehrlich M, Gama-Sosa MA, Huang L-H, Midgett RM, Kuo KC, McCune RA, Gehrke C. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues or cells. *Nucleic Acids Res* 1982; 10:2709-21; PMID:7079182; <https://doi.org/10.1093/nar/10.8.2709>
12. Globisch D, Münzel M, Müller M, Michalakakis S, Wagner M, Koch S, Brückl T, Biel M, Carell T. Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. *PLoS One* 2010; 5:e15367; PMID:21203455; <https://doi.org/10.1371/journal.pone.0015367>
13. Koziol MJ, Bradshaw CR, Allen GE, Costa AS, Frezza C, Gurdon JB. Identification of methylated deoxyadenosines in vertebrates reveals diversity in DNA modifications. *Nat Struct Mol Biol* 2016; 23:24-30; PMID:26689968; <https://doi.org/10.1038/nsmb.3145>
14. Liu J, Zhu Y, Luo GZ, Wang X, Yue Y, Wang X, Zong X, Chen K, Yin H, Fu Y. Abundant DNA 6mA methylation during early embryogenesis of zebrafish and pig. *Nat Commun* 2016; 7:13052; PMID:27713410; <https://doi.org/10.1038/ncomms13052>
15. Greer EL, Blanco MA, Gu L, Sendinc E, Liu J, Aristizabal-Corrales D, Hsu CH, Aravind L, He C, Shi Y. DNA methylation on N6-Adenine in *C. elegans*. *Cell* 2015; 161:868-78; PMID:25936839; <https://doi.org/10.1016/j.cell.2015.04.005>
16. Zhang G, Huang H, Liu D, Cheng Y, Liu X, Zhang W, Yin R, Zhang D, Zhang P, Liu J, et al. N6-methyladenine DNA modification in *Drosophila*. *Cell* 2015; 161:893-906; PMID:25936838; <https://doi.org/10.1016/j.cell.2015.04.018>
17. Fu Y, Luo GZ, Chen K, Deng X, Yu M, Han D, Hao Z, Liu J, Lu X, Doré LC, et al. N6-methyldeoxyadenosine marks active transcription start sites in *Chlamydomonas*. *Cell* 2015; 161:879-92; PMID:25936837; <https://doi.org/10.1016/j.cell.2015.04.010>
18. Wu TP, Wang T, Seetin MG, Lai Y, Zhu S, Lin K, Liu Y, Byrum SD, Mackintosh SG, Zhong M, et al. DNA methylation on N(6)-adenine in mammalian embryonic stem cells. *Nature* 2016; 532:329-33; PMID:27027282; <https://doi.org/10.1038/nature17640>
19. Koziol MJ, Bradshaw CR, Allen GE, Costa AS, Frezza C, Gurdon JB. Identification of methylated deoxyadenosines in vertebrates reveals diversity in DNA modifications. *Nat Struct Mol Biol* 2016; 23:24-30; PMID:26689968; <https://doi.org/10.1038/nsmb.3145>
20. Schiffers S, Ebert C, Rahimoff R, Kosmatchev O, Steinbacher J, Bohne A-V, Spada F, Michalakakis S, Nickelsen J, Müller M, et al. Quantitative LC-MS provides no evidence for m6da or m4dc in the genome of mouse embryonic stem cells and tissues. *Angew Chem Int Ed* 2017; PMID:28371147; <https://doi.org/10.1002/anie.201700424>
21. Kumar S, Cheng X, Klimasauskas S, Mi S, Postfai J, Roberts RJ, Wilson GG. The DNA (cytosine-5) methyltransferases. *Nucleic Acids Res* 1993; 22:1-10; PMID:8127644; <https://doi.org/10.1093/nar/22.1.1>
22. Smith SS, Kaplan BE, Sowers LC, Newman EM. Mechanism of human methyl-directed DNA methyltransferases and the fidelity of cytosine methylation. *Proc Natl Acad Sci USA* 1992; 89:4744-8; PMID:1584813; <https://doi.org/10.1073/pnas.89.10.4744>
23. Hori H. Methylated nucleosides in tRNA and tRNA methyltransferases. *Front Genet* 2014; 5:144; PMID:24904644; <https://doi.org/10.3389/fgene.2014.00144>
24. Bestor T, Laudano A, Mattaliano R, Ingram V. Cloning and sequencing of a cDNA encoding dna methyltransferase of mouse cells. *J Mol Biol* 1988; 203:971-83; PMID:3210246; [https://doi.org/10.1016/0022-2836\(88\)90122-2](https://doi.org/10.1016/0022-2836(88)90122-2)
25. Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. *Nat Genet* 1998; 19:219-20; PMID:9662389; <https://doi.org/10.1038/890>
26. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. *Cell* 1999; 99:247-57; PMID:10555141; [https://doi.org/10.1016/S0092-8674\(00\)81656-6](https://doi.org/10.1016/S0092-8674(00)81656-6)
27. Pradhan S, Bacolla A, Wells RD, Roberts RJ. Recombinant human DNA (Cytosine-5) methyltransferase. *J Biol Chem* 1999; 274:33002-10; PMID:10551868; <https://doi.org/10.1074/jbc.274.46.33002>
28. Klose RJ, Bird AP. Genomic DNA methylation: The mark and its mediators. *Trends Biochem Sci* 2006; 31:89-97; PMID:16403636; <https://doi.org/10.1016/j.tibs.2005.12.008>
29. Spada F, Haemmer A, Kuch D, Rothbauer U, Schermelleh L, Kremmer E, Carell T, Längst G, Leonhardt H. DNMT1 but not its interaction with the replication machinery is required for maintenance of DNA methylation in human cells. *J Cell Biol* 2007; 176:565-71; PMID:17312023; <https://doi.org/10.1083/jcb.200610062>
30. Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. *Cell* 1992; 69:915-26; PMID:1606615; [https://doi.org/10.1016/0092-8674\(92\)90611-F](https://doi.org/10.1016/0092-8674(92)90611-F)
31. Stadler MB, Murr R, Burger L, Ivanek R, Lienert F, Scholer A, van Nimwegen E, Wirbelauer C, Oakeley EJ, Gaidatzis D, et al. DNA-binding factors shape the mouse methylome at distal regulatory regions. *Nature* 2011; 480:490-5; PMID:22170606; <https://doi.org/10.1038/nature10716>
32. Ramsahoye BH, Biniszkiwicz D, Lyko F, Clark V, Bird AP, Jaenisch R. Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. *Proc Natl Acad Sci USA* 2000; 97:5237-42; PMID:10805783; <https://doi.org/10.1073/pnas.97.10.5237>
33. Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, Nery JR, Lee L, Ye Z, Ngo QM, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. *Nature* 2009; 462:315-22; PMID:19829295; <https://doi.org/10.1038/nature08514>
34. Xie W, Barr CL, Kim A, Yue F, Lee AY, Eubanks J, Dempster EL, Ren B. Base-resolution analyses of sequence and parent-of-origin dependent DNA methylation in the mouse genome. *Cell* 2012; 148:816-31; PMID:22341451; <https://doi.org/10.1016/j.cell.2011.12.035>
35. Suzuki MM, Bird A. DNA methylation landscapes: Provocative insights from epigenomics. *Nat Rev Genet* 2008; 9:465-76; PMID:18463664; <https://doi.org/10.1038/nrg2341>
36. Bird A, Taggart M, Frommer M, Miller OJ, Macleod D. A fraction of the mouse genome that is derived from islands of nonmethylated, CpG-rich DNA. *Cell* 1985; 40:91-9; PMID:2981636; [https://doi.org/10.1016/0092-8674\(85\)90312-5](https://doi.org/10.1016/0092-8674(85)90312-5)
37. Bird AP. CpG-rich islands and the function of DNA methylation. *Nature* 1986; 321:209-13; PMID:2423876; <https://doi.org/10.1038/321209a0>
38. Antequera F, Bird A. Number of CpG islands and genes in human and mouse. *Proc Natl Acad Sci USA* 1993; 90:11995-9; PMID:7505451; <https://doi.org/10.1073/pnas.90.24.11995>
39. Fatemi M, Pao MM, Jeong S, Gal-Yam EN, Egger G, Weisenberger DJ, Jones PA. Footprinting of mammalian promoters: Use of a CpG DNA methyltransferase revealing nucleosome positions at a single molecule level. *Nucleic Acids Res* 2005; 33:e176; PMID:16314307; <https://doi.org/10.1093/nar/gni180>
40. Boyes J, Bird A. DNA methylation inhibits transcription indirectly via a methyl-CpG binding protein. *Cell* 1991; 64:1123-34; PMID:2004419; [https://doi.org/10.1016/0092-8674\(91\)90267-3](https://doi.org/10.1016/0092-8674(91)90267-3)
41. Siegfried Z, Eden S, Mendelsohn M, Feng X, Tsuberi B-Z, Cedar H. DNA methylation represses transcription in vivo. *Nat Genet* 1999; 22:203-6; PMID:10369268; <https://doi.org/10.1038/9727>
42. Zou S, Toh JDW, Wong KHQ, Gao Y-G, Hong W, Woon EY. N(6)-methyladenosine: A conformational marker that regulates the

- substrate specificity of human demethylases FTO and ALKBH5. *Sci Rep* 2016; 6:25677; PMID:27156733; <https://doi.org/10.1038/srep25677>
43. Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, Yi C, Lindahl T, Pan T, Yang YG, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. *Nat Chem Biol* 2011; 7:885-7; PMID:22002720; <https://doi.org/10.1038/nchembio.687>
 44. Zheng G, Dahl JA, Niu Y, Fedorcsak P, Huang CM, Li CJ, Vågbo CB, Shi Y, Wang WL, Song SH, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. *Mol Cell* 2013; 49:18-29; PMID:23177736; <https://doi.org/10.1016/j.molcel.2012.10.015>
 45. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. *Science* 2009; 324:930-5; PMID:19372391; <https://doi.org/10.1126/science.1170116>
 46. Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, He C, Zhang Y. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. *Science* 2011; 333:1300-3; PMID:21778364; <https://doi.org/10.1126/science.1210597>
 47. Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in purkinje neurons and the brain. *Science* 2009; 324:929-30; PMID:19372393; <https://doi.org/10.1126/science.1169786>
 48. Bachman M, Uribe-Lewis S, Yang X, Williams M, Murrell A, Balasubramanian S. 5-Hydroxymethylcytosine is a predominantly stable DNA modification. *Nat Chem* 2014; 6:1049-55; PMID:25411882; <https://doi.org/10.1038/nchem.2064>
 49. Wagner M, Steinbacher J, Kraus TF, Michalakis S, Hackner B, Pfaffeneder T, Perera A, Müller M, Giese A, Kretschmar HA, et al. Age-dependent levels of 5-methyl-, 5-hydroxymethyl-, and 5-formylcytosine in human and mouse brain tissues. *Angew Chem Int Ed Engl* 2015; 54:12511-4; PMID:26137924; <https://doi.org/10.1002/anie.201502722>
 50. Mellen M, Ayata P, Dewell S, Kriaucionis S, Heintz N. MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system. *Cell* 2012; 151:1417-30; PMID:23260135; <https://doi.org/10.1016/j.cell.2012.11.022>
 51. Perera A, Eisen D, Wagner M, Laube SK, Künzel AF, Koch S, Steinbacher J, Schulze E, Splith V, Mittermeier N, et al. TET3 is recruited by REST for context-specific hydroxymethylation and induction of gene expression. *Cell Rep* 2015; 11:283-94; PMID:25843715; <https://doi.org/10.1016/j.celrep.2015.03.020>
 52. Costa Y, Ding J, Theunissen TW, Faiola F, Hore TA, Shliha PV, Fidalgo M, Saunders A, Lawrence M, Dietmann S, et al. NANOG-dependent function of TET1 and TET2 in establishment of pluripotency. *Nature* 2013; 495:370-4; PMID:23395962; <https://doi.org/10.1038/nature11925>
 53. Koh KP, Yabuuchi A, Rao S, Huang Y, Cunniff K, Nardone J, Laiho A, Tahiliani M, Sommer CA, Mostoslavsky G, et al. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. *Cell Stem Cell* 2011; 8:200-13; PMID:21295276; <https://doi.org/10.1016/j.stem.2011.01.008>
 54. Szwagierczak A, Bultmann S, Schmidt CS, Spada F, Leonhardt H. Sensitive enzymatic quantification of 5-hydroxymethylcytosine in genomic DNA. *Nucleic Acids Res* 2010; 38:e181; PMID:20685817; <https://doi.org/10.1093/nar/gkq684>
 55. Gu TP, Guo F, Yang H, Wu HP, Xu GF, Liu W, Xie ZG, Shi L, He X, Jin SG, et al. The role of TET3 DNA dioxygenase in epigenetic reprogramming by oocytes. *Nature* 2011; 477:606-10; PMID:21892189; <https://doi.org/10.1038/nature10443>
 56. Penn NW, Suwalski R, O'Riley C, Bojanowski K, Yura R. The presence of 5-hydroxymethylcytosine in animal deoxyribonucleic acid. *Biochem J* 1972; 126:781-90; PMID:4538516; <https://doi.org/10.1042/bj1260781>
 57. Globisch D, Münzel M, Müller M, Michalakis S, Wagner M, Koch S, Brückl T, Biel M, Carell T. Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. *PLoS One* 2010; 5:e15367; PMID:21203455; <https://doi.org/10.1371/journal.pone.0015367>
 58. Bachman M, Uribe-Lewis S, Yang X, Burgess HE, Iurlaro M, Reik W, Murrell A, Balasubramanian S. 5-Formylcytosine can be a stable DNA modification in mammals. *Nat Chem Biol* 2015; 11:555-7; PMID:26098680; <https://doi.org/10.1038/nchembio.1848>
 59. Zhu C, Gao Y, Guo H, Xia B, Song J, Wu X, Zeng H, Kee K, Tang F, Yi C. Single-cell 5-formylcytosine landscapes of mammalian early embryos and escs at single-base resolution. *Cell Stem Cell* 2017; 20:720-731.e5; PMID:28343982; <https://doi.org/10.1016/j.stem.2017.02.013>
 60. Mayer W, Niveleau A, Walter J, Fundele R, Haaf T. Embryogenesis: Demethylation of the zygotic paternal genome. *Nature* 2000; 403:501-2; PMID:10676950; <https://doi.org/10.1038/35000656>
 61. Oswald J, Engemann S, Lane N, Mayer W, Olek A, Fundele R, Dean W, Reik W, Walter J. Active demethylation of the paternal genome in the mouse zygote. *Curr Biol* 2000; 10:475-8; PMID:10801417; [https://doi.org/10.1016/S0960-9822\(00\)00448-6](https://doi.org/10.1016/S0960-9822(00)00448-6)
 62. Feng S, Jacobsen SE, Reik W. Epigenetic reprogramming in plant and animal development. *Science* 2010; 330:622-7; PMID:21030646; <https://doi.org/10.1126/science.1190614>
 63. Sasaki H, Matsui Y. Epigenetic events in mammalian germ-cell development: Reprogramming and beyond. *Nat Rev Genet* 2008; 9:129-40; PMID:18197165; <https://doi.org/10.1038/nrg2295>
 64. Guo JU, Ma DK, Mo H, Ball MP, Jang M-H, Bonaguidi MA, Balazer JA, Eaves HL, Xie B, Ford E, et al. Neuronal activity modifies the DNA methylation landscape in the adult brain. *Nat Neurosci* 2011; 14:1345-51; PMID:21874013; <https://doi.org/10.1038/nn.2900>
 65. Morris MJ, Monteggia LM. Role of DNA methylation and the DNA methyltransferases in learning and memory. *Dialogues Clin Neurosci* 2014; 16:359-71; PMID:25364286
 66. Ma DK, Jang M-H, Guo JU, Kitabatake Y, Chang M-I, Pow-anpongkul N, Flavell RA, Lu B, Ming GL, Song H. Neuronal activity-induced gadd45b promotes epigenetic DNA demethylation and adult neurogenesis. *Science* 2009; 323:1074-7; PMID:19119186; <https://doi.org/10.1126/science.1166859>
 67. Seisenberger S, Peat JR, Reik W. Conceptual links between DNA methylation reprogramming in the early embryo and primordial germ cells. *Curr Opin Cell Biol* 2013; 25:281-8; PMID:23510682; <https://doi.org/10.1016/j.celb.2013.02.013>
 68. Schiesser S, Hackner B, Pfaffeneder T, Müller M, Hagemeyer C, Truss M, Carell T. Mechanism and stem-cell activity of 5-carboxycytosine decarboxylation determined by isotope tracing. *Angew Chem Int Ed Engl* 2012; 51:6516-20; PMID:22644704; <https://doi.org/10.1002/anie.201202583>
 69. Liutkevičiūtė Z, Lukinavičius G, Masevičius V, Daujotyte D, Klimaišauskas S. Cytosine-5-methyltransferases add aldehydes to DNA. *Nat Chem Biol* 2009; 5:400-2; PMID:19430486; <https://doi.org/10.1038/nchembio.172>
 70. Haag S, Sloan KE, Ranjan N, Warda AS, Kretschmer J, Blessing C, Hübnér B, Seikowski J, Dennerlein S, Rehling P, et al. NSUN3 and ABH1 modify the wobble position of mt-tRNA Met to expand codon recognition in mitochondrial translation. *EMBO J* 2016; 35:2104-19; PMID:27497299; <https://doi.org/10.15252/embj.201694885>
 71. Liu F, Clark W, Luo G, Wang X, Fu Y, Wei J, Wang X, Hao Z, Dai Q, Zheng G, et al. ALKBH1-mediated tRNA demethylation regulates translation. *Cell* 2016; 167:816-28.e16; PMID:27745969; <https://doi.org/10.1016/j.cell.2016.09.038>
 72. Delatte B, Wang F, Ngoc LV, Collignon E, Bonvin E, Deplus R, Calonne E, Hassabi B, Putmans P, Awe S, et al. Transcriptome-wide distribution and function of RNA hydroxymethylcytosine. *Science* 2016; 351:282-5; PMID:26816380; <https://doi.org/10.1126/science.aac5253>
 73. Fu L, Guerrero CR, Zhong N, Amato NJ, Liu Y, Liu S, Cai Q, Ji D, Jin SG, Niedernhofer LJ, et al. Tet-mediated formation of 5-hydroxymethylcytosine in RNA. *J Am Chem Soc* 2014; 136:11582-5; PMID:25073028; <https://doi.org/10.1021/ja505305z>
 74. Zhang H-Y, Xiong J, Qi B-L, Feng Y-Q, Yuan B-F. The existence of 5-hydroxymethylcytosine and 5-formylcytosine in both DNA and RNA in mammals. *Chem Commun* 2016; 52:737-40; PMID:26562407; <https://doi.org/10.1039/C5CC07354E>
 75. Maiti A, Drohat AC. Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine: Potential implications for

- active demethylation of CpG sites. *J Biol Chem* 2011; 286:35334-8; PMID:21862836; <https://doi.org/10.1074/jbc.C111.284620>
76. He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q, Ding J, Jia Y, Chen Z, Li L, et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. *Science* 2011; 333:1303-7; PMID:21817016; <https://doi.org/10.1126/science.1210944>
 77. Schomacher L, Han D, Musheev MU, Arab K, Kienhofer S, von Seggern A, Niehrs C. Neil DNA glycosylases promote substrate turnover by Tdg during DNA demethylation. *Nat Struct Mol Biol* 2016; 23:116-24; PMID:26751644; <https://doi.org/10.1038/nsmb.3151>
 78. Cortellino S, Xu J, Sannai M, Moore R, Caretti E, Cigliano A, Le Coz M, Devarajan K, Wessels A, Soprano D, et al. Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. *Cell* 2011; 146:67-79; PMID:21722948; <https://doi.org/10.1016/j.cell.2011.06.020>
 79. Cortazar D, Kunz C, Selfridge J, Lettieri T, Saito Y, MacDougall E, Wirtz A, Schuermann D, Jacobs AL, Siegrist F, et al. Embryonic lethal phenotype reveals a function of TDG in maintaining epigenetic stability. *Nature* 2011; 470:419-23; PMID:21278727; <https://doi.org/10.1038/nature09672>
 80. Amouroux R, Nashun B, Shirane K, Nakagawa S, Hill PW, D'Souza Z, Nakayama M, Matsuda M, Turp A, Ndjetehe E, et al. De novo DNA methylation drives 5hmC accumulation in mouse zygotes. *Nat Cell Biol* 2016; 18:225-33; PMID:26751286; <https://doi.org/10.1038/ncb3296>
 81. Santos F, Peat J, Burgess H, Rada C, Reik W, Dean W. Active demethylation in mouse zygotes involves cytosine deamination and base excision repair. *Epigenetics Chromatin* 2013; 6:39; PMID:24279473; <https://doi.org/10.1186/1756-8935-6-39>
 82. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. *Nature* 2010; 468:839-43; PMID:21057493; <https://doi.org/10.1038/nature09586>
 83. Esteller M. Epigenetics in Cancer. *N Engl J Med* 2008; 358:1148-59; PMID:18337604; <https://doi.org/10.1056/NEJMra072067>
 84. Jones PA, Baylin SB. The epigenomics of cancer. *Cell* 2007; 128:683-92; PMID:17320506; <https://doi.org/10.1016/j.cell.2007.01.029>
 85. Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. *Cell* 2005; 123:437-48; PMID:16269335; <https://doi.org/10.1016/j.cell.2005.08.011>
 86. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa J-PJ. CpG island methylator phenotype in colorectal cancer. *Proc Natl Acad Sci USA* 1999; 96:8681-6; PMID:10411935; <https://doi.org/10.1073/pnas.96.15.8681>
 87. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. *Nat Genet* 2006; 38:787-93; PMID:16804544; <https://doi.org/10.1038/ng1834>
 88. Issa J-P. CpG island methylator phenotype in cancer. *Nat Rev Cancer* 2004; 4:988-93; PMID:15573120; <https://doi.org/10.1038/nrc1507>
 89. Ono R, Taki T, Taketani T, Taniwaki M, Kobayashi H, Hayashi Y. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). *Cancer Res* 2002; 62:4075-80; PMID:12124344
 90. Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu J, Xu ZD, Zhu HG, Ling ZQ, Ye D, et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. *Oncogene* 2013; 32:663-9; PMID:22391558; <https://doi.org/10.1038/onc.2012.67>
 91. Neri F, Dettori D, Incarnato D, Krepelova A, Rapelli S, Maldotti M, Parlato C, Paliogiannis P, Oliviero S. TET1 is a tumour suppressor that inhibits colon cancer growth by derepressing inhibitors of the WNT pathway. *Oncogene* 2015; 34:168-76; PMID:25362856; <https://doi.org/10.1038/onc.2014.356>
 92. Hsu C-H, Peng K-L, Kang M-L, Chen Y-R, Yang Y-C, Tsai C-H, Chu CS, Jeng YM, Chen YT, Lin FM, et al. TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. *Cell Rep* 2012; 2:568-79; PMID:22999938; <https://doi.org/10.1016/j.celrep.2012.08.030>
 93. Liu C, Liu L, Chen X, Shen J, Shan J, Xu Y, Yang Z, Wu L, Xia F, Bie P, et al. Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1. *PLoS One* 2013; 8:e62828; PMID:23671639; <https://doi.org/10.1371/journal.pone.0062828>
 94. Langemeijer SMC, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Stevens-Linders E, van Hoogen P, van Kessel AG, Raymakers RA, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. *Nat Genet* 2009; 41:838-42; PMID:19483684; <https://doi.org/10.1038/ng.391>
 95. Lemonnier F, Couronné L, Parrons M, Jaïs J-P, Travert M, Lamant L, Tournillac O, Rousset T, Fabiani B, Cairns RA, et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. *Blood* 2012; 120:1466-9; PMID:22760778; <https://doi.org/10.1182/blood-2012-02-408542>
 96. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim S-H, Ito S, Yang C, Wang P, Xiao MT, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α -ketoglutarate-dependent dioxygenases. *Cancer Cell* 2011; 19:17-30; PMID:21251613; <https://doi.org/10.1016/j.ccr.2010.12.014>
 97. Inoue S, Lemonnier F, Mak TW. Roles of IDH1/2 and TET2 mutations in myeloid disorders. *Int J Hematol* 2016; 103:627-33; PMID:26980223; <https://doi.org/10.1007/s12185-016-1973-7>
 98. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. *Nat Rev Cancer* 2012; 12:599-612; PMID:22898539; <https://doi.org/10.1038/nrc3343>
 99. Thienpont B, Steinbacher J, Zhao H, D'Anna F, Kuchnio A, Ploumakis A, Ghesquière B, Van Dyck L, Boeckx B, Schoonjans L, et al. Tumour hypoxia causes DNA hypermethylation by reducing TET activity. *Nature* 2016; 537:63-8; PMID:27533040; <https://doi.org/10.1038/nature19081>
 100. Yang H, Lin H, Xu H, Zhang L, Cheng L, Wen B, Shou J, Guan K, Xiong Y, Ye D. TET-catalyzed 5-methylcytosine hydroxylation is dynamically regulated by metabolites. *Cell Res* 2014; 24:1017-20; PMID:24971736; <https://doi.org/10.1038/cr.2014.81>
 101. Sciacovelli M, Goncalves E, Johnson TI, Zecchini VR, da Costa AS, Gaude E, Drubbel AV, Theobald SJ, Abbo SR, Tran MG, et al. Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition. *Nature* 2016; 537:544-7; PMID:27580029; <https://doi.org/10.1038/nature19353>
 102. Carey BW, Finley LW, Cross JR, Allis CD, Thompson CB. Intracellular alpha-ketoglutarate maintains the pluripotency of embryonic stem cells. *Nature* 2015; 518:413-6; PMID:25487152; <https://doi.org/10.1038/nature13981>
 103. TeSlaa T, Chaikovskiy AC, Lipchina I, Escobar SL, Hochedlinger K, Huang J, Graeber TG, Braas D, Teitell MA. alpha-ketoglutarate accelerates the initial differentiation of primed human pluripotent stem cells. *Cell Metab* 2016; 24:485-93; PMID:27476976; <https://doi.org/10.1016/j.cmet.2016.07.002>
 104. Yang Q, Liang X, Sun X, Zhang L, Fu X, Rogers CJ, Berim A, Zhang S, Wang S, Wang B, et al. AMPK/alpha-ketoglutarate axis dynamically mediates dna demethylation in the prdm16 promoter and brown adipogenesis. *Cell Metab* 2016; 24:542-54; PMID:27641099; <https://doi.org/10.1016/j.cmet.2016.08.010>
 105. Laukka T, Mariani CJ, Ihantola T, Cao JZ, Hokkanen J, Kaelin WG Jr, Godley LA, Koivunen P. Fumarate and succinate regulate expression of hypoxia-inducible genes via TET enzymes. *J Biol Chem* 2016; 291:4256-65; PMID:26703470; <https://doi.org/10.1074/jbc.M115.688762>